savvas petanidis

Dr. savvas petanidis

Aristotle University, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
EKEfrosini Kioseoglou
Efrosini Kioseoglou
SPsavvas petanidis
savvas petanidis
CGCatherine Gabriel
Catherine Gabriel
ASAthanasios Salifoglou
Athanasios Salifoglou

Verified
Journal Article
Open access
PDF file
DADoxakis Anestakis
Doxakis Anestakis
SPsavvas petanidis
savvas petanidis
SKSpyridon Kalyvas
Spyridon Kalyvas
CNChristiane M. Nday
Christiane M. Nday
OTOlga Tsave
Olga Tsave
Athanasios SalifoglouAthanasios Salifoglou
Athanasios Salifoglou
Over the past years, advances in cancer immunotherapy have resulted in innovative and novel approaches in molecular cancer diagnostics and cancer therapeutic procedures. However, due to tumor heterogeneity and inter-tumoral discrepancy in tumor immunity, the clinical benefits are quite restricted. The goal of this review is to evaluate the major cytokines-interleukins involved in cancer immunotherapy and project their basic biochemical and clinical applications. Emphasis will be given to new cytokines in pre-clinical development, and potential directions for future investigation using cytokines. Furthermore, current interleukin-based approaches and clinical trial data from combination cancer immunotherapies will also be discussed. It appears that continuously increasing comprehension of cytokine-induced effects, cancer stemness, immunoediting, immune-surveillance as well as understanding of molecular interactions emerging in the tumor microenvironment and involving microRNAs, autophagy, epithelial-mesenchymal transition (EMT), inflammation, and DNA methylation processes may hold much promise in improving anti-tumor immunity. To this end, the emerging in-depth knowledge supports further studies on optimal synergistic combinations and additional adjuvant therapies to realize the full potential of cytokines as immunotherapeutic agents.

1 August 2015 in Cellular Signalling
Verified
Journal Article
Closed access
Paul ZarogoulidisPaul Zarogoulidis
Paul Zarogoulidis
SPsavvas petanidis
savvas petanidis
EKEfrosini Kioseoglou
Efrosini Kioseoglou
KDKalliopi Domvri
Kalliopi Domvri
DADoxakis Anestakis
Doxakis Anestakis
KZKonstantinos Zarogoulidis
Konstantinos Zarogoulidis

6 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPsavvas petanidis
savvas petanidis
DADoxakis Anestakis
Doxakis Anestakis
MAMaria Argyraki
Maria Argyraki
MHMargarita Hadzopoulou-Cladaras
Margarita Hadzopoulou-Cladaras
Athanasios SalifoglouAthanasios Salifoglou
Athanasios Salifoglou
Recent studies have suggested that aberrant K-ras signaling is responsible for triggering immunological responses and inflammation-driven tumorigenesis. Interleukins IL-17, IL-22, and IL-23 have been reported in various types of malignancies, but the exact mechanistic role of these molecules remains to be elucidated. Given the role of K-ras and the involvement of interleukins in colorectal tumorigenesis, research efforts are reported for the first time, showing that differentially expressed interleukin IL-17, IL-22, and IL-23 levels are associated with K-ras in a stage-specific fashion along colorectal cancer progression. Specifically, a) the effect of K-ras signaling was investigated in the overall expression of interleukins in patients with colorectal cancer and healthy controls, and b) an association was established between mutant K-ras and cytokines GM-CSF and IFN-γ. The results indicate that specific interleukins are differentially expressed in K-ras positive patients and the use of K-ras inhibitor Manumycin A decreases both interleukin levels and apoptosis in Caco-2 cells by inhibiting cell viability. Finally, inflammation-driven GM-CSF and IFN-γ levels are modulated through interleukin expression in tumor patients, with interleukin expression in the intestinal lumen and cancerous tissue mediated by aberrant K-ras signaling. Collectively, the findings a) indicate that interleukin expression is influenced by ras signaling and specific interleukins play an oncogenic promoter role in colorectal cancer, highlighting the molecular link between inflammation and tumorigenesis, and b) accentuate the interwoven molecular correlations as leads to new therapeutic approaches in the future.

11 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
TKTHEODORA KATOPODI
THEODORA KATOPODI
SPsavvas petanidis
savvas petanidis
CCCharalampos Charalampidis
Charalampos Charalampidis
Ioanna P. ChatziprodromidouIoanna P. Chatziprodromidou
Ioanna P. Chatziprodromidou
PEPANAGIOTIS ESKITZIS
PANAGIOTIS ESKITZIS
Konstantinos PorpodisKonstantinos Porpodis
Konstantinos Porpodis
The tumor microenvironment plays a key role in progression of tumorigenesis, tumor progression, and metastasis. Accumulating data reveal that dendritic cells (DCs) appear to play a key role in the development and progression of metastatic neoplasia by driving immune system dysfunction and establishing immunosuppression, which is vital for tumor evasion of host immune response. Consequently, in this review, we will discuss the function of tumor-infiltrating DCs in immune cell signaling pathways that lead to treatment resistance, tumor recurrence, and immunosuppression. We will also review DC metabolism, differentiation, and plasticity, which are essential for metastasis and the development of lung tumors. Furthermore, we will take into account the interaction between myeloid cells and DCs in tumor-related immunosuppression. We will specifically look into the molecular immune-related mechanisms in the tumor microenvironment that result in reduced drug sensitivity and tumor relapse, as well as methods for combating drug resistance and focusing on immunosuppressive tumor networks. DCs play a crucial role in modulating the immune response. Especially, as cancer progresses, DCs may switch from playing an immunostimulatory to an inhibitory role. This article’s main emphasis is on tumor-infiltrating DCs. We address how they affect tumor growth and expansion, and we highlight innovative approaches for therapeutic modulation of these immunosuppressive DCs which is necessary for future personalized therapeutic approaches.

1 January 2016 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
OTOlga Tsave
Olga Tsave
SPsavvas petanidis
savvas petanidis
EKEfrosini Kioseoglou
Efrosini Kioseoglou
MYMaria P Yavropoulou
Maria P Yavropoulou
JYJohn G Yovos
John G Yovos
Athanasios SalifoglouAthanasios Salifoglou
Athanasios Salifoglou
Over the last decade, a diverse spectrum of vanadium compounds has arisen as anti‐inflammatory therapeutic metallodrugs targeting various diseases. Recent studies have demonstrated that select well‐defined vanadium species are involved in many immune‐driven molecular mechanisms that regulate and influence immune responses. In addition, advances in cell immunotherapy have relied on the use of metallodrugs to create a “safe,” highly regulated, environment for optimal control of immune response. Emerging findings include optimal regulation of B/T cell signaling and expression of immune suppressive or anti‐inflammatory cytokines, critical for immune cell effector functions. Furthermore, in‐depth perusals have explored NF‐κB and Toll‐like receptor signaling mechanisms in order to enhance adaptive immune responses and promote recruitment or conversion of inflammatory cells to immunodeficient tissues. Consequently, well‐defined vanadium metallodrugs, poised to access and resensitize the immune microenvironment, interact with various biomolecular targets, such as B cells, T cells, interleukin markers, and transcription factors, thereby influencing and affecting immune signaling. A synthetically formulated and structure‐based (bio)chemical reactivity account of vanadoforms emerges as a plausible strategy for designing drugs characterized by selectivity and specificity, with respect to the cellular molecular targets intimately linked to immune responses, thereby giving rise to a challenging field linked to the development of immune system vanadodrugs.